In essence, the objective would be to activate the endogenous barrier-promoting and anti-inflammatory actions of GLP-1 signaling prior to SARS-CoV-2 infection, with the prospect that this would increase resilience in the event of infection. The gene discussed is GCG; the disease is infection.